• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

How to manage iron toxicity in post-allogeneic hematopoietic stem cell transplantation?

作者信息

Kontoghiorghes George J

机构信息

Postgraduate Research Institute of Science Technology, Environment and Medicine, Limassol, Cyprus.

出版信息

Expert Rev Hematol. 2020 Apr;13(4):299-302. doi: 10.1080/17474086.2020.1719359. Epub 2020 Feb 8.

DOI:10.1080/17474086.2020.1719359
PMID:32037922
Abstract
摘要

相似文献

1
How to manage iron toxicity in post-allogeneic hematopoietic stem cell transplantation?如何处理异基因造血干细胞移植后的铁中毒？
Expert Rev Hematol. 2020 Apr;13(4):299-302. doi: 10.1080/17474086.2020.1719359. Epub 2020 Feb 8.
2
One-year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantation.一项前瞻性随机试验的一年期结果，该试验比较了静脉放血术与地拉罗司治疗重型地中海贫血患儿根治性干细胞移植后铁过载的疗效。
Pediatr Blood Cancer. 2017 Jan;64(1):188-196. doi: 10.1002/pbc.26213. Epub 2016 Aug 31.
3
A prospective study of iron overload management in allogeneic hematopoietic cell transplantation survivors.异基因造血细胞移植幸存者中铁过载管理的前瞻性研究。
Biol Blood Marrow Transplant. 2010 Jun;16(6):832-7. doi: 10.1016/j.bbmt.2010.01.004. Epub 2010 Jan 14.
4
Iron overload and allogeneic hematopoietic stem-cell transplantation.铁过载与异基因造血干细胞移植。
Expert Rev Hematol. 2011 Feb;4(1):71-80. doi: 10.1586/ehm.10.81.
5
Management of iron overload before, during, and after hematopoietic stem cell transplantation for thalassemia major.重型地中海贫血患者造血干细胞移植前、中、后铁过载的管理。
Ann N Y Acad Sci. 2016 Mar;1368(1):115-21. doi: 10.1111/nyas.13027. Epub 2016 Mar 21.
6
A prospective cohort study of the feasibility and efficacy of iron reduction by phlebotomy in recipients of hematopoietic SCT.一项关于放血疗法降低造血干细胞移植受者铁含量的可行性和疗效的前瞻性队列研究。
Bone Marrow Transplant. 2015 Mar;50(3):457-8. doi: 10.1038/bmt.2014.273. Epub 2014 Dec 15.
7
Iron overload in patients receiving allogeneic hematopoietic stem cell transplantation: quantification of iron burden by a superconducting quantum interference device (SQUID) and therapeutic effectiveness of phlebotomy.异体造血干细胞移植患者的铁过载：超导量子干涉仪（SQUID）定量铁负荷和放血疗法的疗效。
Biol Blood Marrow Transplant. 2010 Jan;16(1):115-22. doi: 10.1016/j.bbmt.2009.09.011. Epub 2009 Sep 18.
8
[Assessment and management of post-transplant iron overload: Guidelines of the Francophone Society of Marrow Transplantation and Cellular Therapy (SFGM-TC)].[移植后铁过载的评估与管理：法语国家骨髓移植与细胞治疗协会（SFGM-TC）指南]
Bull Cancer. 2016 Nov;103(11S):S255-S266. doi: 10.1016/j.bulcan.2016.09.003. Epub 2016 Nov 11.
9
Iron overload in hematopoietic cell transplantation.造血细胞移植中的铁过载
Bone Marrow Transplant. 2008 Jun;41(12):997-1003. doi: 10.1038/bmt.2008.99. Epub 2008 Apr 28.
10
Efficacy and safety of oral deferasirox treatment in the posttransplant period for patients who have undergone allogeneic hematopoietic stem cell transplantation (alloHSCT).异基因造血干细胞移植（alloHSCT）后口服地拉罗司治疗的疗效和安全性。
Ann Hematol. 2012 May;91(5):743-749. doi: 10.1007/s00277-011-1358-1. Epub 2011 Nov 4.

引用本文的文献

1
New Insights into Aspirin's Anticancer Activity: The Predominant Role of Its Iron-Chelating Antioxidant Metabolites.阿司匹林抗癌活性的新见解：其铁螯合抗氧化代谢产物的主要作用
Antioxidants (Basel). 2024 Dec 29;14(1):29. doi: 10.3390/antiox14010029.
2
The Importance and Essentiality of Natural and Synthetic Chelators in Medicine: Increased Prospects for the Effective Treatment of Iron Overload and Iron Deficiency.天然和合成螯合剂在医学中的重要性和必要性：有效治疗铁过载和缺铁症的前景增加。
Int J Mol Sci. 2024 Apr 25;25(9):4654. doi: 10.3390/ijms25094654.
3
Targeting ferroptosis for leukemia therapy: exploring novel strategies from its mechanisms and role in leukemia based on nanotechnology.
针对白血病治疗的铁死亡靶向治疗：基于纳米技术从机制和白血病中的作用探索新策略。
Eur J Med Res. 2024 Apr 9;29(1):224. doi: 10.1186/s40001-024-01822-7.
4
Drug Selection and Posology, Optimal Therapies and Risk/Benefit Assessment in Medicine: The Paradigm of Iron-Chelating Drugs.药物选择和剂量、医学中的最佳治疗和风险/效益评估：铁螯合剂药物的范例。
Int J Mol Sci. 2023 Nov 25;24(23):16749. doi: 10.3390/ijms242316749.
5
Iron Load Toxicity in Medicine: From Molecular and Cellular Aspects to Clinical Implications.医学中的铁负荷毒性：从分子和细胞角度到临床意义。
Int J Mol Sci. 2023 Aug 18;24(16):12928. doi: 10.3390/ijms241612928.
6
The Vital Role Played by Deferiprone in the Transition of Thalassaemia from a Fatal to a Chronic Disease and Challenges in Its Repurposing for Use in Non-Iron-Loaded Diseases.去铁酮在将地中海贫血从致命疾病转变为慢性疾病过程中所起的关键作用及其在非铁过载疾病中重新应用面临的挑战
Pharmaceuticals (Basel). 2023 Jul 18;16(7):1016. doi: 10.3390/ph16071016.
7
Metal Complexes of Omadine (-Hydroxypyridine-2-thione): Differences of Antioxidant and Pro-Oxidant Behavior in Light and Dark Conditions with Possible Toxicity Implications.奥马汀（-羟基吡啶-2-硫酮）金属配合物：在光照和黑暗条件下抗氧化和促氧化行为的差异及其可能的毒性意义。
Molecules. 2023 May 20;28(10):4210. doi: 10.3390/molecules28104210.
8
Deferiprone and Iron-Maltol: Forty Years since Their Discovery and Insights into Their Drug Design, Development, Clinical Use and Future Prospects.地拉罗司和铁-麦芽酚：从发现到药物设计、研发、临床应用及未来前景的四十年。
Int J Mol Sci. 2023 Mar 4;24(5):4970. doi: 10.3390/ijms24054970.
9
New Iron Metabolic Pathways and Chelation Targeting Strategies Affecting the Treatment of All Types and Stages of Cancer.新型铁代谢途径和螯合靶向策略影响各种类型和阶段癌症的治疗。
Int J Mol Sci. 2022 Nov 13;23(22):13990. doi: 10.3390/ijms232213990.
10
Deferiprone: A Forty-Year-Old Multi-Targeting Drug with Possible Activity against COVID-19 and Diseases of Similar Symptomatology.地拉罗司：一种具有 40 年历史的多靶点药物，可能对 COVID-19 和具有相似症状的疾病具有活性。
Int J Mol Sci. 2022 Jun 16;23(12):6735. doi: 10.3390/ijms23126735.